GenomeQuest Announces Patent Sequence Database, GQ-PAT
News May 08, 2007
GenomeQuest, Inc. has announced that its GQ-PAT repository has surpassed 66 million patent number-sequence pairs, culled from U.S. and worldwide patents.
GQ-PAT is a core content component of the company GenomeQuest™ 4.0 web-enabled platform for sequence search and results analysis.
Including GQ-PAT, GenomeQuest™ has a sequence database numbering 137 million records, whose sources include multiple global databases – patent offices, publicly available bio-sequence databases and web resources.
Given the diverse content quality from various sources, data entered into GQ-PAT are meticulously processed in GenomeQuest’s proprietary automated pipeline to make the sequences, as well as all the annotations, searchable and browsable.
GQ-PAT data is both automatically filtered and manually curated to detect and eliminate errors originating from source databases. All sequence patent records are annotated from the original patent documents, to make sure key data fields are complete, including Patent Title, Abstract, Publication Date, Priority Dates, Patent Assignee, and other critical information.
In addition, INPADOC services are used to provide updates on the legal status of the patent records as well as to provide the latest patent family information.
Ronald Ranauro, President and CEO of GenomeQuest, Inc., said, “It is clear the latest release of GQ-PAT extends our leadership in patent sequence comprehensiveness, annotation quality, and timeliness, which translates into reliable and fresh content for our customers. When combined with breakthrough GenomeQuest search algorithms and results analysis, our customers can make rapid and confident decisions and more easily communicate throughout their organizations thereby ensuring better decision making earlier in their research and development cycle.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.